The most extraordinary thing happened to me while researching this article. I listen to dozens of corporate presentations each month while researching my investment possibilities (which must be added to the list of things terribly wrong with me - because I actually enjoy them) but this is the wackiest thing I've ever heard.
So, I think Nektar is very well positioned to move towards a positive cash flow. If you look at what we have either in Phase 3, or filed programs, it's pretty impressive. In Phase 3 we have Amikacin Inhale, and I'll talk about some of these
Only subscribers can access this article, which is part of the PRO research library covering 3,587 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: